We recently published 10 Firms Stealing Market Spotlight Amid Bloodbath. Metsera, Inc. (NASDAQ:MTSR) is one of the ...

The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.

Novo Nordisk has raised its offer to buy out obesity biotech Metsera to $10bn as a bidding war with Pfizer intensifies. This ...

Novo Nordisk has lowered its full-year profit and sales forecasts amid slowed sales growth. However, a better-than-expected ...

Management reassured investors that there could be substantial value in its lead drug candidate, VK2735.